NASDAQ · SIGA

SIGA Technologies Inc.

$3.11 -$0.04 (-1.27%) 1D Market open

Key Metrics

$225.93M
Market cap
11.17×
P/E · TTM
$93.78M
Revenue · TTM
$20.23M
Net income
EPS · TTM $0.28
Dividend yield
Free cash flow
Beta · 1Y 0.81
EBITDA · TTM $27.49M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Feb 2 high, the share price fell 55%.

    Peak close $6.95 on Feb 2; trough close $3.11 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -55%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 25
    The stock moved -8.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 25
  • Apr 7
    The stock moved -12.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 7

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$225.93M
Enterprise value
Shares outstanding71.7M
52-wk range$3.03 – $9.62
Avg volume · 20D1.4M
Net cash
Book value / share$2.12
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About SIGA Technologies Inc.
IPO dateSep 9, 1997
Employees49

SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E11.17
P/S2.41
P/FCF
EV/EBITDA
EV/Sales
Graham №$3.68

Profitability

Gross
Operating 28.7%
Net 21.6%
FCF
ROE / ROIC 11.0% · 333.9%

Financial Health

Current ratio3.25
Quick ratio2.38
Debt / equity
Debt / EBITDA
Net cash
Working capital$146.37M

Cash Flow · TTM

Operating CF $27.75M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

3.1
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$3.68 vs $3.11
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings